Abstract
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea;......
小提示:本篇文献需要登录阅读全文,点击跳转登录